Interim report
Page 1
BACTIGUARD HOLDING AB | BACTIGUARD.COM INTERIM REPORT THIRD QUARTER 2026 Accelerating performance validates our partnership model Third quarter 2026 (July – September) • Total revenue amounted to SEK 58.4 (48.4) million, an increase of SEK 10.0 million corresponding to 20.6%. • Net sales amounted to SEK 55.1 (45.5) million, an increase of SEK 9.7 million corresponding to 21.2%. Adjusted for currency effects of SEK 1.1 million, net sales increased by 23.6%. • Operating profit amounted to SEK 6.8 (-6.4) million. • EBITDA amounted to SEK 17.5 (5.3) million with a margin of 30.0% (10.9%). • Adjusted EBITDA amounted to SEK 20.0 (5.3) million with a margin of 34.3% (10.9%). • Net profit for the period amounted to SEK 7.3 (-7.5) million. • Profit per share, before and after dilution, amounted to SEK 0.25 (-0.21). • Cash flow from operating activities amounted to SEK 14.0 (-2.8) million corresponding to SEK 0.39 (-0.08) per share. • Net debt excluding lease liabilities amounted to SEK 64.2 (83.0) million. The period January – September 2026 • Total revenue amounted to SEK 162.4 (163.2) million, a decrease of SEK 0.8 million corresponding to 0.5%. • Net sales amounted to SEK 151.6 (152.8) million, a decrease of SEK 1.2 million corresponding to 0.8%. Adjusted for currency effects of SEK 7.9 million, net sales increased by 4.4%. • Operating loss amounted to SEK 8.6 (16.3) million. • EBITDA amounted to SEK 24.3 (19.1) million with a margin of 15.0% (1 1.7 %). • Adjusted EBITDA amounted to SEK 30.6 (19.1) million with a margin of 18.8% (11.7%). • Net loss for the period amounted to SEK 6.5 (20.4) million. • Loss per share, before and after dilution, amounted to SEK 0.14 (0.59). • Cash flow from operating activities amounted to SEK 18.7 (-13.2) million corresponding to SEK 0.53 (-0.38) per share. 1 Defined according to IFRS. 2 Alternative performance measure. For definition and reconciliation, see pages 16-17. Key figures Full year RTM 2026 2025 2026 2025 2025 2025/26 Total revenue¹,MSEK 58.4 48.4 162.4 163.2 228.8 227.9 Operating profit/loss¹,MSEK 6.8 -6.4 -8.6 -16.3 -3.3 4.4 EBITDA²,MSEK 17.5 5.3 24.3 19.1 43.8 49.0 EBITDA margin²,% 30.0 10.9 15.0 11.7 19.1 21.5 Adjusted EBITDA²,MSEK 20.0 5.3 30.6 19.1 43.8 55.3 Net profit/loss for the period¹,MSEK 7.3 -7.5 -6.5 -20.4 -7.8 6.0 Earnings per share¹,SEK 0.25 -0.21 -0.14 -0.59 -0.22 0.22 Cash flow from operating activities ¹,MSEK 14.0 -2.8 18.7 -13.2 -1.5 30.4 Cash flow from operating activities, per share²,SEK 0.39 -0.08 0.53 -0.38 -0.04 0.87 Equity ratio²,% 59.8 55.4 59.8 55.4 57.8 59.8 Net debt²,MSEK 98.7 128.7 98.7 128.7 118.7 98.7 Jan-SepJul-Sep
Page 2
INTERIM REPORT THIRD QUARTER 2026 | 2 CEO statement Q3 2026 Accelerating performance validates our partnership model We are pleased to report a very strong third quarter, following the solid second quarter, demonstrating the scalability of the partnership business model and the results our execution delivers. Advancing the building blocks for partnership growth and new partnership generation Demand for Bactiguard-coated products remained strong, and during the quarter we carried out further commercialization activities together with our partners. We work across the value chain from coating technology through commercialization encompassing process and product development, regulatory approvals and sales & marketing training to help partners bring products successfully to patients. We continued to advance regulatory programs that support product approvals, market access and future commercialization. Over the past two years we have expanded our regulatory expertise and direct dialogue with authorities, including the FDA, to facilitate an efficient product approval process for partners. Our growing involvement in this work shows how the value we bring to partners increasingly extends beyond the noble metal technology itself. We also strengthened our scientific evidence including new publications. In September we presented new data at leading orthopedic congresses demonstrating both the durability of the coating and the differentiation of the technology, which has no market equivalent. Within business development, orthopedics remains the area where partner engagement is strongest, reflecting the well-recognized need for infection prevention in implant surgery and increasing focus among payers on the economic burden of infections. During the quarter, we deepened our engagement and made meaningful headway across several initiatives, further reinforcing the significant avenues for future partnership development within this therapeutic area. Strong market demand lifts profitability Revenues from our Becton, Dickinson & Company (BD) partnership were the key contributor to the performance in the third quarter with a growth of more than 30 percent. The long-standing markets continued to perform well, and markets launched over the past two years are now generating increasing order volumes, reflecting the cumulative impact of our cooperation and development efforts. The growth in the partnership with BD is the strongest we have seen in a decade. Under the amended agreement with Zimmer Biomet, royalty generation is now more closely linked to underlying market performance. During the quarter we saw double-digit growth from royalties based on product sales driven by a growing market demand. After a very strong second quarter, Wound Management had a softer third quarter, reflecting the inherent quarterly variability of the business as well as product phasing. Despite this Wound Management grew double digits organically over the first nine months, led by Hydrocyn aqua. Because our business is built to run lean, our growth translated into strong underlying earnings in the third quarter. Adjusted EBITDA of 20 million SEK in the quarter and 55 million SEK over the last twelve months is our strongest profitability since the shift to a license-based business. Cash flow from operating activities was equally strong at SEK 14 million for the quarter, and 30 million SEK over the last twelve months, further demonstrating the strength and scalability of our business model. Outlook: building on our momentum We see good reasons for optimism. The progress with BD and our collaboration with Zimmer further strengthens our conviction in the long-term potential of the partnerships and their strategic importance to Bactiguard. We expect continued positive growth within our license business, supported by growing market traction and increasing demand in recently launched markets. Across our ongoing new partner dialogues, we see an interest that reinforces our confidence in the opportunities ahead and our efforts in business development remain firmly focused on advancing these discussions towards agreements. The long-term outlook for Wound Management remains equally positive. We believe that the underlying market dynamics, together with the continued expansion of Hydrocyn aqua, provide a solid foundation for future profitable growth. We remain committed to disciplined cost management while investing in the priorities that enable our long-term growth ambitions. Christine Lind, CEO
Page 3
INTERIM REPORT THIRD QUARTER 2026 | 3 Business model Bactiguard is a global MedTech company developing safe and biocompatible technology to prevent medical device related infections. The company’s unique technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard’s infection prevention solutions decrease patient suffering, save lives, and unburden healthcare resources while also fighting against antimicrobial resistance, one of the most serious threats to global health and modern medicine. Bactiguard operates through license partnerships with leading global MedTech companies that apply the infection prevention technology to their medical devices and sell them under their own brand or co-branded with Bactiguard. Our license-focused business model is scalable with operational leverage. Partnerships across three phases Bactiguard’s license revenues have three components: we receive revenues for coating and process development, we receive revenues for the right to use the coating technology on medical devices within a specific application and geographical area, and we receive royalties – a variable remuneration once the license partners’ products reach the market. The revenues are generated across three partnership phases: application development, exclusivity and license. An application development partner works in close collaboration with Bactiguard’s R&D team exploring the application of our infection prevention technology to the partners’ underlying device to enhance its performance. The nature of development work means that not every project will succeed, but the learnings are valuable for other application areas. An exclusivity partner gets exclusive rights to apply our coating technology to a certain medical device but has no products in the market yet, for instance due to pending regulatory approvals, which can take time depending on the type of application and its classification. A license partner has the right to market and sell medical devices with Bactiguard’s coating technology, in a certain region or globally. Not all partnerships will follow all three phases. An agreement with a partner can generate revenues from separate phases and components simultaneously. Partnerships Application area Market Becton, Dickinson & Company (BD) Urinary catheters (Foley) Exclusive global market rights (excl. China) Zimmer Biomet Trauma implants, ZNN Bactiguard Non-exclusive global market rights (excl. Southeast Asia, China, India, and South Korea) Well Lead Medical Urinary catheters Exclusive market rights in China
Page 4
INTERIM REPORT THIRD QUARTER 2026 | 4 Development in the third quarter Revenue Total revenue for the third quarter amounted to SEK 58.4 (48.4) million, an increase of SEK 10.0 million, corresponding to 20.8 percent. Adjusted for currency effects of SEK 0.1 million, revenue increased by 21.1 percent. Net sales amounted to SEK 55.1 (45.5) million, an increase of SEK 9.7 million, corresponding to 21.2 percent. Adjusted for currency effects of SEK 1.1 million, net sales increased by 23.6 percent. Total license revenue amounted to SEK 41.0 (29.9) million, an increase of SEK 11.1 million, corresponding to 37.5 percent. Adjusted for currency effects of SEK 0.9 million, total license revenues increased by 40.4 percent. Revenues from Becton Dickinson & Company (BD) amounted to SEK 37.6 (28.3) million, an increase of SEK 9.4 million, corresponding to 33.1 percent. Adjusted for currency effects of SEK -0.9 million, revenues from BD increased by 30.0 percent. The growth pertains to concentrate sales and royalties from positive development in both existing and new markets. Revenues from Zimmer Biomet amounted to SEK 3.4 (1.5) million, an increase of SEK 1.9 million, corresponding to 125.1 percent. Adjusted for currency effects of SEK -0.1 million, revenues from Zimmer increased by 117.6 percent. The increase pertains partly to the comparison period last year where no minimum royalties or fixed fees was recognized. In the quarter, we see positive double-digit growth in royalties from product sales. Revenues from license partners amounted to SEK 40.9 (29.8) million, an increase of SEK 11.1 million, corresponding to 37.4 percent. Adjusted for currency effects of SEK 0.9 million, revenues from license partners increased by 40.4 percent. Revenues from exclusivity partners amounted to SEK 0.0 (0.0) million. Revenues from application development partners amounted to SEK 0.1 (0.1) million. Revenues from Wound Management portfolio amounted to SEK 14.1 (15.6) million, a decrease of SEK 1.5 million, corresponding to 9.9 percent. Adjusted for currency effects of SEK 0.2 million, revenues from Wound Management portfolio decreased by 8.8 per cent. The decrease mainly pertains to order phasing and we continue to expect Wound Management to deliver double-digit growth. Revenues from the BIP portfolio amounted to SEK 0.0 (0.0) million. As planned, we do not expect any significant BIP revenues in 2026. Other revenues amounted to SEK 3.3 (2.9) million, an increase of SEK 0.4 million, corresponding to 14.8 percent. Currency effects amounted to SEK 0.9 (0.8) million and the remaining revenue primarily relates to rent income. Result Costs for raw materials and consumables for the third quarter amounted to SEK -8.2 (-6.5) million, an increase of SEK 1.7 million, corresponding to 26.0 percent. Other external costs amounted to SEK -12.2 (-11.3) million. Personnel costs amounted to SEK -22.4 (-24.4) million, a decrease of SEK 2.0 million, corresponding to 8.1 percent. Other operating expenses are related to currency exchange losses/gains, which amounted to SEK -1.3 *Revenue at constant currency Reported revenue Jul-Sep Organic growth Jul-Sep Jul-Sep Growth MSEK 2026 % 2026 2025 % Total license revenue 41.9 40.4 41.0 29.9 37.5 License partners 41.8 40. 4 40.9 29.8 37.4 Exclusivity partners - - - - - Application development partners 0.1 79.4 0.1 0.1 - Wound Management portfolio 14.3 -8.8 14.1 15.6 -9.9 BIP portfolio - - - 0. 0 - Net sales 56.2 23.6 55.1 45.5 21.2 Other operating revenues 2.4 -17.7 3.3 2.9 14.8 Total revenue 58.5 21.1 58.4 48.4 20.8 *Constant-currency figures are translated using the prior-year average exchange rates.
Page 5
INTERIM REPORT THIRD QUARTER 2026 | 5 (-0.9) million. Total operating expenses (OPEX) amounted to SEK -35.9 (-36.6) million, a decrease of SEK 0.7 million, corresponding to 2.0 percent. The operating profit amounted to SEK 6.8 (-6.4) million, an increase of SEK 13.2 million, corresponding to 205.6 percent. The improved result is mainly pertained to higher license revenue driven by positive development in both existing and new markets. EBITDA for the third quarter amounted to SEK 17.5 (5.3) million, an increase of SEK 12.3 million. The EBITDA margin was 30.0 (10.9) percent. Adjusted EBITDA for the third quarter amounted to SEK 20.0 (5.3) million with a margin of 34.3 (10.9) percent. Depreciation and amortization amounted to SEK -10.7 (-11.7) million, a decrease of SEK 1.0 million, corresponding to 8.4 percent. Amortization of intangible assets amounted to SEK -6.5 (-7.1) million, attributable primarily to amortization of SEK -6.0 (-6.4) million related to Bactiguard’s technology. Depreciation of tangible assets amounted to SEK -4.4 (-4.6) million, primarily attributable to depreciation on leasing of SEK -3.1 (-3.2) million. Financial items amounted to SEK -0.8 (-2.5) million. Financial income amounted to SEK 1.2 (0.1) million. Financial expenses amounted to SEK -2.0 (-2.6) million which mainly pertained to interest expenses of SEK -1.7 (-2.1) million. Current tax for the period amounted to SEK 0.0 (0.0) million. Change in deferred tax amounted to SEK 1.3 (1.4) million attributable to the intangible assets and leases, which is calculated at the Swedish tax rate of 20.6 percent. Income tax in foreign subsidiaries is calculated on the basis of a tax rate of 24.0 percent. Net profit for the third quarter of 2026 amounted to SEK 7.3 (-7.5) million. Development during the period January – September Revenue Total revenue for the period January to September amounted to SEK 162.4 (163.2) million, a decrease of SEK 0.8 million, corresponding to 0.5 percent. Adjusted for currency effects of SEK 4.0 million total revenue increased with 2.0 percent. Net sales amounted to SEK 151.6 (152.8) million, a decrease of SEK 1.2 million, corresponding to 0.8 percent. Adjusted for currency effects of SEK 7.9 m illion, n et sales increased by 4.4 percent. Total license revenue amounted to SEK 98.2 (103.2) million, a decrease of SEK 5.0 million, corresponding to 4.9 percent. Adjusted for currency effects of SEK 5.8 million, total license revenues increased by 0.7 percent. Revenues from Becton Dickinson & Company (BD) amounted to SEK 86.9 (79.7) million, an increase of SEK 7.2 million, corresponding to 9.1 percent. Adjusted for currency effects of SEK 5.5 million, revenues from BD increased by 16.0 percent. Revenues from Zimmer Biomet amounted to SEK 11.2 (16.5) million, a decrease of SEK 5.3 million, corresponding to 32.0 percent. Adjusted for currency effects of SEK 0.4 million, revenues from Zimmer Biomet decreased by 29.9 percent. The higher level of Zimmer Biomet revenues during the same period 2025 pertained mainly to minimum royalties under the previous agreement with Zimmer Biomet. Revenues from license partners amounted to SEK 96.9 (103.1) million, a decrease of SEK 6.2 million, corresponding to 6.0 percent. Adjusted for currency effects of SEK 5.8 million, revenues from license partners decreased by 0.4 percent. *Revenue at constant currency Reported revenue Jan -Sep Organic growth Full year RTM Organic growth Growth Full year R TM Growth MSEK 2026 % 2025 2025/ 26 % 2026 2025 % 2025 2025/26 % Total license revenue 104.0 0. 7 163.3 159.9 -2.1 98.2 103.2 -4.9 152.3 147.3 -3.3 License partners 102.7 - 0.4 163.0 158.3 -2.9 96.9 103.1 -6.0 152.0 145.8 -4.1 Exclusivity partners - - - - - - - - - - - Application development partners 1.3 - 0. 3 1.6 434.2 1.3 0.1 - 0.3 1.5 - Wound Management portfolio 55.5 13. 9 63.1 69.8 10.6 53.4 48.7 9.7 62.7 67.5 7.5 BIP portfolio - - 0. 9 - - - 0.9 - 0.9 - - Net sales 159.4 4. 4 227.3 229.7 1.0 151.6 152.8 -0.8 215.9 214.7 -0.6 Other operating revenues 7.0 - 32.5 9.6 9.1 -5.6 10.8 10.4 4.5 12.8 13.2 2.9 Total revenue 166.5 2.0 237. 0 238.8 0.8 162.4 163.2 -0.5 228.8 227.9 -0.4 *Constant-currency figures are translated using the prior-year average exchange rates. Jan-Sep
Page 6
INTERIM REPORT THIRD QUARTER 2026 | 6 Revenues from exclusivity partners amounted to SEK 0.0 (0.0) million. Revenues from application development partners amounted to SEK 1.3 (0.1) million. Revenues from Wound Management portfolio amounted to SEK 53.4 (48.7) million, an increase of SEK 4.7 million, corresponding to 9.7 percent. Adjusted for currency effects of SEK 2.1 million, revenues from Wound Management portfolio increased by 13.9 percent. This mainly pertains to growth of Hydrocyn aqua. Revenues from the BIP portfolio amounted to SEK 0.0 (0.9) million. As planned, we do not expect any significant BIP revenues in 2026. Other revenues amounted to SEK 10.8 (10.4) million, an increase of SEK 0.5 million, corresponding to 4.5 percent. Currency effects amounted to SEK 3.8 (2.9) million and the remaining revenue primarily relates to rent income. Result Costs for raw materials and consumables for the period January to September amounted to SEK -23.4 (-24.3) million, a decrease of SEK 0.9 million, corresponding to 3.7 percent. Other external costs amounted to SEK -44.0 (-43.1) million. Personnel costs amounted to SEK -70.8 (-70.9) million, a decrease of SEK 0.2 million, corresponding to 0.2 percent. Other operating expenses are related to currency exchange losses/gains, which amounted to SEK -5.6 (-5.8) million. In total operating expenses (OPEX) amounted to SEK -120.4 (-119.9) million, an increase of SEK 0.5 million, corresponding to 0.4 percent. The operating loss amounted to SEK 8.6 (16.3) million, a decrease of SEK 7.7 million, corresponding to 47.3 percent. The improved result is mainly pertained to higher license revenue driven by positive development in both existing and new markets. EBITDA for the period January to September amounted to SEK 24.3 (19.1) million, an increase of SEK 5.2 million. EBITDA margin was 15.0 (11.7) percent. Adjusted EBITDA for the period January to September amounted to SEK 30.6 (19.1) million with a margin of 18.8 (11.7) percent. Depreciation and amortization amounted to SEK -32.9 (-35.4) million, a decrease of SEK 2.5 million, corresponding to 7.1 percent. Amortization of intangible assets amounted to SEK -19.8 (-21.2) million, attributable primarily to amortization of SEK -18.1 (-19.1) million related to Bactiguard’s technology. Depreciation of fixed assets amounted to SEK -13.1 (-14.2) million, primarily attributable to depreciation on leasing of SEK -9.2 (-9.7) million. Financial items amounted to SEK -2.8 (-9.9) million. Financial income amounted to SEK 3.1 (0.1) million while financial expenses amounted to SEK -5.9 (-10.0) million which mainly pertained to interest expenses of SEK -5.1 (-6.7) million. Current tax for the period amounted to SEK 0.0 (0.0) million. Change in deferred tax amounted to SEK 4.9 (5.9) million attributable to the intangible assets and leases, which is calculated at the Swedish tax rate of 20.6 percent. Income tax in foreign subsidiaries is calculated on the basis of a tax rate of 24.0 percent. Net loss for the period January to September of 2026 amounted to SEK 6.5 (20.4) million. Cash flow Cash flow from operating activities for the quarter amounted to SEK 14.0 (-2.8) million and for the period January to September to SEK 18.7 (-13.2) million. Change in working capital for the quarter amounted to SEK -2.5 (-17.5) million and for the period January to September to SEK 4.5 (-21.4) million. Cash flow from investing activities for the quarter amounted to SEK -0.2 (-2.5) million and for the period January to September to SEK -1.4 (-4.4) million. Cash flow from financing activities for the quarter amounted to SEK -3.4 (-3.1) million and for the period January to September to -9.6 (-59.0), the 2025 number is mainly pertained to the amortization of SEK 51.0 million of the financing with SEB done in Q1 2025. Cash flow for the quarter amounted to SEK 10.4 (-8.4) million and for the period January to September to SEK 7.7 (-76.5) million. Cash and cash equivalents at the end of the period of 30 September 2026 amounted to SEK 55.1 (37.4) million.
Page 7
INTERIM REPORT THIRD QUARTER 2026 | 7 Financial position Equity on 30 September 2026 amounted to SEK 313.3 (301.5) million and net debt to SEK 98.7 (128.7) million. Total assets on 30 September 2026 amounted to SEK 524.2 (544.6) million. As of 30 September 2026, the parent company’s liabilities with SEB amounted to SEK 120.0 (120.0) million. As of 30 September 2026, the approved overdraft facility from SEB of SEK 30 million was not utilized. Foreign subsidiaries had credit facilities amounting to SEK 8.7 (7.9) million, of which SEK 0.0 (1.6) million was utilized as of 30 September 2026. Employees Full-time equivalents in the Group during the period January to September averaged to 156 (161) FTE of which 105 (101) are women. On 30 September 2026, the number of full-time equivalents was 166 FTE. The share and share capital Bactiguard's B share is listed on Nasdaq Stockholm with the short name "BACTI B". The closing price for the B share was SEK 15.7 (20.2) on 30 September 2026 and the market capitalization amounted to SEK 561 (708) million. The share capital in Bactiguard on 30 September 2026 amounted to SEK 0.9 (0.9) million divided into 715,000 Class C shares with one vote each (715,000 votes), 31,043,885 Class B shares with one vote each (31,043,885 votes) and 4,000,000 Class A shares with ten votes each (40,000,000 votes). The total number of shares and votes in Bactiguard on 30 September 2026 was 35,758,885 shares and 71,758,885 votes. Ownership 1 Company controlled by Thomas von Koch. Per 30 September 2026 Bactiguard had 2,692 (2,885) shareholders. Key events Key events during the quarter The Board of Bactiguard Holding AB has on the 8 July 2026, pursuant to authorisations granted by the annual general meeting on 19 May 2026, resolved on a directed issue and immediate repurchase of 715,000 Class C shares. The measures are intended to ensure the Company’s ability to deliver shares to participants in the share- based long-term incentive plan 2026 (“LTIP 2026”) adopted by the annual general meeting if, and to the extent that, the relevant performance conditions are satisfied during the plan’s performance measurement period. The number of shares and votes in Bactiguard Holding AB has increased during July 2026 as a result of the new issue of Class C shares to secure the Company’s commitments under the LTIP 2026. All Class C shares have been repurchased by the Company and will be converted into Class B shares in connection with the delivery of Class B shares to participants under the terms of LTIP 2026. Shareholders No. of A shares No. of B shares No. of C shares Total number % of capital % of votes TomBact AB¹ 4,000,000 11,447,615 15,447,615 43.2 71.7 Nordea Funds AB 3,721,094 3,721,094 10.4 5.2 STÅHLBERG JAN INGE 3,605,150 3,605,150 10.1 5.0 FJÄRDE AP-FONDEN 3,475,992 3,475,992 9.7 4.8 Handelsbanken FonderAB 1,796,925 1,796,925 5.0 2.5 FörsäkringsaktiebolagetAvanza Pension 849,326 849,326 2.4 1.2 Lancelot AssetManagement AB 600,000 600,000 1.7 0.8 SEB Funds AB 437,797 437,797 1.2 0.6 SEB LIFEINTERNATIONALASSURANCE 393,000 393,000 1.1 0.6 Lind Christine Anne 389,500 389,500 1.1 0.5 Total, major shareholders 4,000,000 26,716,399 30,716,399 85.9 93.0 Total, others 4,327,486 4,327,486 12.1 6.0 Treasury shares 715,000 715,000 2.0 1.0 Total number of shares 4,000,000 31,043,885 715,000 35,758,885 100.0 100.0
Page 8
INTERIM REPORT THIRD QUARTER 2026 | 8 TomBact AB acquired 2,000,000 Class A shares and 4,106,957 Class B shares in Bactiguard Holding AB from Christian Kinch on 27 August 2026. The acquired holding corresponds to approximately 17 percent of the total number of shares and approximately 34 percent of the voting rights in the Company. The transaction was completed after market close at a premium of 56 percent to Bactiguard Holding AB's closing share price on 27 August 2026. Bactiguard Holding AB announced on the 17 September 2026 the release of previously unpublished data on its noble metal technology that highlight its distinct and durable properties for orthopedic implants. The new data were presented at the 37th Annual Congress of the International Society for Technology in Arthroplasty (ISTA). Key events after the end of the quarter No key events after the end of the quarter. Financial targets The company’s financial targets relate to growth and profitability and are expected to be delivered by year-end 2030. The financial and strategic targets should not be perceived as a forecast but rather reflect what Bactiguard’s Board of Directors and Executive Management consider to be reasonable mid-term expectations given the sharpened license focused strategy. Revenues: deliver revenues of at least SEK 600 million by year-end 2030 EBITDA: deliver an EBITDA of at least SEK 200 million by year-end 2030 Partnership development: have at least ten application areas in either exclusivity partnerships or license partnerships by year-end 2030 Other information Accounting and valuation principles The consolidated financial statements are prepared in accordance with the International Financial Reporting Standards (IFRS). The interim report has been prepared in accordance with IAS 34 Interim Reporting and the Annual Accounts Act. Disclosures in accordance with IAS 34 Interim Reporting are submitted both in notes and elsewhere in the interim report. The parent company’s financial statements have been prepared in accordance with the Annual Accounts Act and the Financial Reporting Board's recommendation, RFR 2 Accounting for Legal Entities. Accounting and valuation principles are stated in the annual report 2025. The accounting principles are unchanged from previous periods. Segment reporting An operating segment is a component of an entity that engages in business activities from which it may derive revenues and incur expenses, whose operating results are regularly reviewed by the chief operating decision maker and for which there is separate financial information. The company's reporting of operating segments is consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker is the function that assesses the operating segment performance and decides how to allocate resources. The company has determined that the Group’s executive management constitutes of the chief operating decision maker. The company is considered in its entirety to operate within one business segment. Parent company During the period, the parent company has received compensation for services and interest in its receivables from group companies. No investments were made during the period. Risk factors Companies within the Group are exposed to various types of risk through their activities. Bactiguard continually engages in a process of identifying all risks that may arise and assessing how each of these risks shall be managed. The Group is working to create an overall risk management program that focuses on minimizing potential adverse effects on the company's financial results. The company is primarily exposed to financial risks, market risks, and operational risks. A description of these risks can be found on page 14-15 and 57–59 in the annual report 2025.
Page 9
INTERIM REPORT THIRD QUARTER 2026 | 9 The geopolitical situation and macro trends In addition to identified risks, the macro situation and its impact is continuously monitored. The global healthcare challenges have a significant impact on society. The need for more efficient and safe healthcare is driven by both economic and demographic developments, as well as increased political unrest, conflicts, wars, and natural disasters. Particularly prominent are healthcare-associated infections and antimicrobial resistance where we see an increased interest in infection prevention. Bactiguard does not have suppliers in or sales to any of Russia, Belarus, or Ukraine. However, the global economy is affected by the situation of the war, and we follow developments closely and continuously evaluate the operational and financial effects as the global situation may change and affect the company's financial position. Bactiguard has a subsidiary in Israel. We are closely following the developments there and our primary focus is to ensure the staff’s well-being and security. We make the assessment that the conflict in Israel will have a negligible effect on the group’s result and financial position. The global macroeconomic environment remains uncertain, with developments in inflation, interest rates, currency fluctuations and economic growth potentially affecting the company’s operations and financial performance. Changes in cost levels may impact profitability, as increased costs cannot always be fully passed on to customers. Interest rate movements may affect the financing costs. Bactiguard has substantial USD exposure in the license business and fluctuations in exchange rates may impact the result, see the annual report 2025. The company does not hedge its currency exposure. Developments are monitored closely, given the rapidly evolving landscape.
Page 10
INTERIM REPORT THIRD QUARTER 2026 | 10 Group consolidated income statement Condensed statement of comprehensive income Full year RTM TSEK Note 2026 2025 2026 2025 2025 2025/26 Revenues 1 Net sales 55,115 45,464 151,565 152,753 215,918 214,730 Other operating income 3,313 2,885 10,821 10,451 12,849 13,219 Total 58,428 48,349 162,386 163,204 228,767 227,949 Change in inventory of finished goods and products in progress 3,144 26 5,706 47 2,618 8,277 Raw materials and consumables -8,181 -6,493 -23,397 -24,297 -33,883 -32,983 Other external expenses -12,208 -11,305 -44,005 -43,140 -51,595 -52,460 Personnel costs -22,402 -24,368 -70,770 -70,934 -95,376 -95,212 Depreciation and amortization -10,723 -11,712 -32,898 -35,405 -47,077 -44,570 Other operating expenses -1,255 -940 -5,639 -5,823 -6,776 -6,592 Total -51,625 -54,792 -171,003 -179,552 -232,089 -223,540 Operating profit/loss 6,803 -6,443 -8,616 -16,348 -3,322 4,409 Profit/loss from financial items Financial income 1,202 87 3,136 108 1,392 4,420 Financial expenses -2,010 -2,601 -5,945 -10,008 -12,183 -8,120 Total -808 -2,514 -2,809 -9,900 -10,791 -3,700 Profit/loss before tax 5,995 -8,957 -11,425 -26,248 -14,113 709 Current tax 1 - 46 - -1,019 -973 Deferred tax 1,268 1,441 4,886 5,893 7,288 6,281 NET PROFIT/LOSS FOR THE PERIOD 7,264 -7,516 -6,493 -20,355 -7,844 6,017 Attributable to: The parent company´s shareholders 7,264 -7,516 -6,493 -20,355 -7,844 6,017 Earnings per share before dilution, SEK 0.25 -0.21 -0.14 -0.59 - 0.22 0.22 Earnings per share after dilution, SEK 0.25 -0.21 -0.14 -0.59 -0.22 0.22 Jan-SepJul-Sep Full year RTM TSEK Note 2026 2025 2026 2025 2025 2025/26 Net profit/loss for the period 7,264 -7,516 -6,493 -20,355 -7,844 6,017 Other comprehensive income: Items that will not be reclassified to profit or loss for the year - - - - - - Items that will be reclassified to profit or loss for the year Translation differences 1,376 -367 4,648 -6,507 -5,565 5,590 Other comprehensive income, after tax 1,376 -367 4,648 -6,507 -5,565 5,590 TOTAL COMPREHENSIVE INCOME FOR THE PERIOD 8,639 -7,882 -1,846 -26,861 -13,409 11,607 Attributable to: The parent company´s shareholders 8,639 -7,882 -1,846 -26,861 -13,409 11,607 Number of shares at the end of period ('000) 35,759 35,044 35,759 35,044 35,044 35,759 Weighted average number of shares ('000) 35,044 35,044 35,044 35,044 35,044 35,044 Jul-Sep Jan-Sep
Page 11
INTERIM REPORT THIRD QUARTER 2026 | 11 Group condensed statement of financial position TSEK Note 2026-09-30 2025-09-30 2025-12-31 ASSETS Non-current assets Intangible fixed assets Goodwill 251,498 248,320 248,817 Technology 4,649 29,111 22,771 Brands 25,579 25,579 25,579 Customer relationships 1,505 2,789 2,462 Capitalized development costs 34 792 517 Patent 485 682 605 Total 283,750 307,273 300,751 Tangible assets Right of use lease assets 30,838 41,839 39,684 Buildings 24,313 22,427 22,992 Leasehold improvements 17,253 18,851 18,194 Machinery and other technical plant 4,194 5,180 5,047 Equipment, tools and installations 7,454 7,098 7,426 Total 84,052 95,395 93,343 Financial assets Other non-current receivables 2,873 2,859 2,857 Total 2,873 2,859 2,857 Deferred tax assets 28,748 23,437 23,941 Total non-current assets 399,423 428,964 420,892 Current assets Inventory 29,500 27,138 21,881 Accounts receivable 20,053 28,861 35,757 Other current receivables 2 9,185 10,988 10,197 Prepaid expenses and accrued income 11,024 11,267 12,075 Cash and cash equivalents 55,053 37,422 44,261 Total current assets 124,815 115,676 124,171 TOTAL ASSETS 524,238 544,640 545,063 EQUITY AND LIABILITIES Equity attributable to shareholders of the parent Share capital 894 876 876 Translation reserve 3,207 -2,383 -1,441 Other capital contribution 930,478 930,680 930,680 Retained earnings including net profit/loss for the period -621,253 -627,693 -615,182 Total equity 313,326 301,481 314,933 Non-current liabilities Liabilities to credit institutions 119,267 120,398 119,373 Leasing liabilities 20,018 32,192 29,472 Provisions 5,257 5,257 6,966 Other long-term liabilities - 92 - Total non-current liabilities 144,542 157,939 155,811 Current liabilities Leasing liabilities 14,466 13,530 14,079 Accounts payable 10,562 15,137 17,750 Provisions 3,452 16,297 7,391 Other current liabilities 2 1,472 1,647 2,013 Accrued expenses and prepaid income 36,418 38,609 33,086 Total current liabilities 66,370 85,220 74,319 TOTAL LIABILITIES 210,912 243,159 230,130 TOTAL EQUITY AND LIABILITIES 524,238 544,640 545,063
Page 12
INTERIM REPORT THIRD QUARTER 2026 | 12 Group condensed statement of changes in equity TSEK Share capital Other capital contribution Reserves Retained earnings including net profit/loss for the period Total equity Opening balance 2025-01-01 876 930,680 4,124 -607,338 328,342 Net profit/loss for the period - - - -20,355 -20,355 Other comprehensive income: Translation differences - - -6,507 - -6,507 Total comprehensive income after tax - - -6,507 -20,355 -26,862 Closing balance 2025-09-30 876 930,680 -2,383 -627,693 301,480 Opening balance 2026-01-01 876 930,680 -1,441 -615,182 314,933 Net profit/loss for the period - - - -6,493 -6,493 Other comprehensive income: Translation differences - - 4,648 - 4,648 Total comprehensive income after tax - - 4,648 -6,493 -1,845 New issue 18 - - - 18 Repurchase of own shares - - - -18 -18 Share-based payments - - - 238 238 Total transactions with shareholders 18 - - 220 238 Closing balance 2026-09-30 894 930,680 3,207 -621,455 313,326
Page 13
INTERIM REPORT THIRD QUARTER 2026 | 13 Group condensed statement of cash flows Full year RTM TSEK Note 2026 2025 2026 2025 2025 2025/26 Net profit/loss for the period 7,263 -7,515 -6,494 -20,355 -7,844 6,017 Adjustments for depreciation and amortization and other non-cash items 9,253 22,197 20,646 28,573 33,751 25,824 Increase/decrease inventory -2,745 1,422 -7,204 2,422 7,631 -1,995 Increase/decrease accounts receivable 1,531 -1,388 14,322 -4,599 -13,702 5,219 Increase/decrease other current receivables 858 5,055 2,048 4,063 4,047 2,032 Increase/decrease accounts payable 572 -5,723 -7,188 -7,788 -5,175 -4,575 Increase/decrease other current liabilities -2,763 - 16,845 2,567 -15,492 -20,195 -2,136 Cash flow from changes in working capital -2,547 -17,479 4,545 -21,393 -27,394 -1,456 Cash flow from operating activities 13,969 -2,794 18,697 -13,174 -1,487 30,386 Investments in intangible assets - - - - - - Investments in tangible assets -191 -2,461 -1,440 -4,366 -5,720 -2,794 Cash flow from investing activities -191 -2,461 -1,440 -4,366 -5,720 -2,794 Amortization of leasing liability -3,229 -3,545 -9,453 -8,502 -11,223 -12,174 Amortization of loan - - - -52,048 -51,748 300 Change in bank overdraft -185 420 -106 1,553 228 -1,431 New issue 18 - 18 - - 18 Repurchase of own shares -18 - -18 - - -18 Cash flow from financing activities -3,414 -3,125 -9,559 -58,996 -62,743 -13,306 Cash flow for the period 10,364 -8,380 7,698 -76,538 -69,949 14,287 Cash and cash equivalents at the beginning of the period 43,524 46,100 44,261 116,727 116,727 37,422 Exchange difference in cash and cash equivalents 1,164 -298 3,093 -2,767 -2,517 3,343 Cash and cash equivalents at end of period 55,053 37,422 55,053 37,422 44,261 55,053 Jul-Sep Jan-Sep
Page 14
INTERIM REPORT THIRD QUARTER 2026 | 14 Condensed parent company income statement The parent company presents no separate statement of comprehensive income since the company has no items in 2026 or 2025 recognized in other comprehensive income. Net profit/loss for the period for the parent company thereby also constitutes of the comprehensive income for the period. Full year RTM TSEK Note 2026 2025 2026 2025 2025 2025/26 Net sales 788 660 1,435 1,986 2,833 2,282 Total 788 660 1,435 1,986 2,833 2,282 Other external expenses -902 -686 -2,851 -2,715 -3,728 -3,864 Personnel costs -742 -740 -2,224 -2,291 -3,032 -2,965 Total -1,644 -1,426 -5,075 -5,006 -6,760 -6,829 Operating profit/loss -856 -766 -3,640 -3,020 -3,928 -4,548 Financial income 2,757 3,014 8,373 9,773 12,670 11,270 Financial expenses -1,642 -1,712 -4,659 -5,566 -7,202 -6,295 Total 1,115 1,302 3,714 4,207 5,468 4,975 Income after financial items 258 536 73 1,187 1,541 427 Deferred tax - - - - - - Net profit/loss for the period 258 536 73 1,187 1,541 427 Jan-SepJul-Sep
Page 15
INTERIM REPORT THIRD QUARTER 2026 | 15 Condensed parent company balance sheet TSEK Note 2026-09-30 2025-09-30 2025-12-31 ASSETS Non-current assets Financial assets Shares in subsidiaries 635,429 635,191 635,191 Receivables from group companies 282,677 292,723 290,711 Deferred tax assets 15,255 15, 255 15,255 Total non-current assets 933,360 943,169 941,157 Current assets Current receivables Other current receivables -7 729 1,713 Prepaid expenses and accrued income 74,540 63,677 66,455 Total 74,534 64,406 68, 168 Cash and bank equivalents 2,934 3,193 1,764 Total current assets 77,467 67,599 69,932 TOTAL ASSETS 1,010,828 1,010,768 1,011,089 EQUITY & LIABILITIES E quity Restricted equity Share capital 894 876 876 Total restricted equity 894 876 876 Non-restricted equity Retained earnings -23,405 -25,166 -25,166 Non-restricted share premium 727,767 727,969 727,969 Net profit/loss for the period 73 1,187 1,541 T otal non-restricted equity 704,435 703,990 704,344 Total equity 705,329 704,867 705,220 Non-current liabilities Liabilities to credit institutions 120,000 120,000 120,000 Total non-current liabilities 120,000 120,000 120,000 Current liabilities Liabilities to group companies 184,000 184,000 184,000 Accounts payable -20 220 297 Other current liabilities 128 130 133 A ccrued expenses and prepaid income 1,391 1,552 1,439 Total current liabilities 185,499 185,901 185,869 Total liabilities 305,499 305,901 305,869 TOTAL EQUITY AND LIABILITIES 1,010,828 1,010,768 1,011,089
Page 16
INTERIM REPORT THIRD QUARTER 2026 | 16 Definitions of alternative key performance indicators Bactiguard presents certain financial measures in its annual report that have not been defined in line with IFRS (referred to as alternative key performance indicators as set forth in the ESMA guidelines). It is the opinion of the company that these measures provide useful supplementary information to investors and the company’s management as they allow for the evaluation of the company’s performance. Since not all companies calculate the measures in the same way, these are not always comparable to measures used by other companies. These performance measures should therefore not be considered a substitute for measures as defined under IFRS. The definitions and tables below describe how the performance measures are calculated. The measures are alternative in accordance with ESMA’s guidelines unless otherwise stated. EBITDA EBITDA presents the company’s earning capacity from ongoing operations irrespective of capital structure and tax situation. The key figure is used to facilitate comparisons with other companies in the same industry. The company considers this performance measure to be the most relevant, since the company’s technology is depreciated by large amounts, which does not impact cash flow negatively. Bactiguard’s patented, unique technology can be applied to a broad range of products in the licensing business. The company defines EBITDA as operating profit/loss excluding depreciation and amortization of tangible and intangible assets. EBITDA margin Presents the company’s earning capacity from ongoing operations, irrespective of capital structure and tax situation, in relation to revenues. The key figure is used to facilitate analysis of the company’s result in comparison with comparable companies. Adjusted EBITDA Adjusted EBITDA is presented as an alternative performance measure to illustrate the underlying operating performance by excluding items affecting comparability. A reconciliation to EBITDA is provided below. The Group expects to incur non-recurring costs related to the EU Medical Device Regulations (MDR) during 2026 and 2027. These costs are not considered representative of the underlying operating performance as they do not form part of the Group’s ongoing core operations and are therefore considered non-recurring. To provide a more comparable view of performance, the Group therefore also presents adjusted EBITDA and adjusted EBITDA margin excluding these costs. Full year RTM TSEK 2026 2025 2026 2025 2025 2025/26 Operating profit/loss 6,801 -6,443 -8,617 -16,348 -3,322 4,409 Depreciation 10,723 11,712 32,898 35,405 47,077 44,570 EBITDA 17,524 5,269 24,281 19,057 43,755 48,979 Jul-Sep Jan-Sep Full year RTM TSEK 2026 2025 2026 2025 2025 2025/26 EBITDA 17,524 5,269 24,281 19,057 43,755 48,979 Revenues 58,428 48,349 162,386 163,204 228,767 227,949 EBITDA margin % 30.0 10.9 15.0 11.7 19. 1 21.5 Jul-Sep Jan-Sep Full year RTM TSEK 2026 2025 2026 2025 2025 2025/26 Operating profit/loss 6,801 -6,443 -8,617 -16,348 -3,322 4,409 Depreciation 10,723 11, 712 32,898 35,405 47,077 44,570 EBITDA 17,524 5,269 24,281 19,057 43,755 48,979 Adjustments for MDR-costs 2,511 - 6,233 - - 6,305 Adjusted EBITDA 20,035 5,269 30,586 19,057 43,755 55,284 Jul-Sep Jan-Sep
Page 17
INTERIM REPORT THIRD QUARTER 2026 | 17 Adjusted EBITDA margin Presents the company’s adjusted, as defined above, earning capacity from ongoing operations, irrespective of capital structure and tax situation, in relation to revenues. Net debt Net debt is a measure used to describe the Group’s indebtedness and its ability to repay its debt with cash generated from the Group’s operating activities if the debts matured today. The company considers this key figure interesting for creditors who want to understand the Group’s debt situation. The company defines net debt as interest-bearing liabilities minus cash and cash equivalents at the end of the period. Equity ratio Equity ratio is a measure the company considers important for creditors who want to understand the company’s long-term ability to pay. The company defines equity ratio as equity and untaxed reserves (less deferred tax), in relation to the balance sheet total. Cash flow from operating activities per share Cash flow per share calculated as the cash flow from operating activities divided by the average number of shares outstanding during the period. The key figure is presented because it is used by analysts and other stakeholders to evaluate the company – it shows operating cash flow per share. Profit/loss from financial items Financial income minus financial expenses. Direct reconciliation against financial report is possible. RTM/Rolling 12 months This performance measure implies the twelve months before and including a certain date. Full year RTM TSEK 2026 2025 2026 2025 2025 2025/26 Adjusted EBITDA 20,035 5,269 30,586 19,057 43,755 55,284 Revenues 58,428 48,349 162,386 163,204 228,767 227,949 Adjusted EBITDA margin % 34.3 10.9 18.8 11.7 19. 1 24.3 Jul-Sep Jan-Sep Full year TSEK 2026 2025 2025 Non-current liabilities to credit institutions 119,267 120,398 119,373 Long-term lease debt 20,018 32,192 29,472 Short-term lease debt 14,466 13,530 14,079 Interest-bearing debt 153,751 166,120 162,924 Cash and cash equivalents 55,053 37,422 44,261 Net debt 98,698 128,698 118,663 Jan-Sep Full year TSEK 2026 2025 2025 Equity 313,326 301,481 314,933 Balance sheet total 524,238 544,640 545,063 Equity ratio, % 59.8 55.4 57.8 Jan-Sep
Page 18
INTERIM REPORT THIRD QUARTER 2026 | 18 Note 1 Revenue distribution Note 2 Financial assets and liabilities at fair value The table below shows the breakdown of financial assets and financial liabilities recognized at fair value in the consolidated balance sheet. Distribution of how fair value is determined is based on three levels. Level 1: according to prices quoted on an active market for the same instrument. Level 2: based on directly or indirectly observable market data not included in level 1. Level 3: based on input data that is not observable on the market. For description of how fair values have been calculated, see annual report 2025, note 4. Fair value of financial assets and liabilities are estimated to be substantially consistent with posted values. The balance sheet contains receivables and liabilities from the business that are held to maturity. These are reported at amortized cost, which also constitutes an approximation to fair value. Note 3 Share-based payments At the Annual General Meeting held on 19 May 2026, a new long-term share-based incentive programme, LTIP 2026, was approved. The programme is directed at the CEO, senior executives, managers and selected key employees within the Group. The purpose of the programme is to promote long-term commitment and align the interests of participants with those of the Company's shareholders. LTIP 2026 is accounted for as an equity-settled share-based payment arrangement in accordance with IFRS 2, Share-based Payment. Participants have been granted performance share rights which, subject to continued employment and the fulfilment of predetermined performance conditions, entitle participants to receive shares in Bactiguard Holding AB without consideration. The vesting period runs from July 2026 to June 2029. Vesting is conditional upon continued employment throughout the vesting period and achievement of performance targets linked to the Group's adjusted EBITDA. During the third quarter, the Company issued and immediately repurchased 715,000 Class C shares in order to secure future share deliveries under LTIP 2026. The repurchased shares are held by the Company and are intended to secure future share deliveries in accordance with the programme's terms. The share rights granted under LTIP 2026 correspond to a maximum dilution effect of approximately 2.0 per cent of the total number of shares in the Company. The grant date fair value of each performance share right was determined to SEK 16.65. During the period, an expense of SEK 0.2 million (0.0) was recognised in relation to LTIP 2026, excluding social security contributions. Full year RTM TSEK 2026 2025 2026 2025 2025 2025/26 License partners 40,897 29,771 96,894 103,103 152,030 145,821 Exclusivity partners - - - - - - Application development partners 128 76 1,278 118 294 1,454 Wound Management portfolio 14,091 15,633 53,394 48,674 62,736 67,456 BIP portfolio - -15 - 858 858 - Total 55,115 45,464 151,565 152,753 215,918 214,730 Time for revenue recognition Performance commitment is met at a certain time 54,988 45,389 150,288 152,635 215,624 213,276 Performance commitment is met during a period of time 128 76 1,278 118 294 1,454 Total 55,115 45,464 151,565 152,753 215,918 214,730 Jul-Sep Jan-Sep
Page 19
INTERIM REPORT THIRD QUARTER 2026 | 19 Quarterly information TSEK Q3 2026 Q2 2026 Q1 2026 Q 4 2025 Q3 2025 Q2 2025 RTM 25/26 License partners 40,897 31,751 24,246 48, 927 29,771 34,080 145,821 Exclusivity partners - - - - - - - Application development partners 128 263 887 176 83 -15 1,454 Wound Management portfolio 14,091 21,988 17,315 14,062 15,633 13,840 67,456 BIP portfolio - - - - -15 324 - Other operating revenues 3,313 3,051 4,457 2,398 2,878 3,887 13,219 Total revenue 58,428 57,053 46,905 65,563 48,349 52,115 227,949 EBITDA 17,524 2,632 4,125 24,698 5,269 4,379 48,979 EBITDA margin (%) 30.0 4.6 8.8 37.7 10.9 8.4 21.5 Adjusted EBITDA 20,035 5,630 4,920 24,698 5,269 4,379 55,283 Adjusted EBITDA margin (%) 34.3 9.9 10.5 37.7 10.9 8.4 24.3 EBIT 6,801 -8,250 -7,168 13, 026 -6,443 -7,295 4,409 Net profit/loss for the period 7,262 -8,194 -5,562 12, 511 -7,516 -8,111 6,017 Earnings per share before dilution, SEK 0.25 -0.23 -0.16 0. 36 -0.21 -0.24 0.22 Earnings per share after dilution, SEK 0.25 -0.23 -0.16 0. 36 -0.21 -0.24 0.22 Operating cash flow 13,969 12,442 -7,433 11, 689 -2,794 1,727 30,667 Operating cash flow per share, SEK 0.39 0.36 -0.21 0. 33 -0.08 0.05 0.87 Net debt 98,698 113,567 125,957 118, 663 128,698 123,364 98,698 Total shares (pcs) 35,043,885 35,043,885 35,043,885 35,043,885 35,043,885 35,043,885 35,043,885
Page 20
INTERIM REPORT THIRD QUARTER 2026 | 20 Signatories of the report The Board of Directors and the CEO certify that the interim report, to the best of their knowledge, provides a fair overview of the parent company's and the Group's operations, financial position and results and describes the material risks and uncertainties faced by the parent company and the companies included in the Group. Stockholm 22 October 2026 Thomas von Koch Richard Kuntz Chairperson of the Board Board Member Anna Martling Magdalena Persson Board Member Board Member Jan Ståhlberg Christine Lind Board Member CEO This interim report has been reviewed by the company auditors. This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out below on 22 October 2026, at 07:00 a.m. CET. This is a translation of the Swedish Interim report. In the event of any discrepancy, the Swedish version applies.
Page 21
About Bactiguard Bactiguard is a global MedTech company developing safe and biocompatible technology to prevent medical device related infections. The company’s unique technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard’s infection prevention solutions decrease patient suffering, save lives, and unburden healthcare resources while also fighting against antimicrobial resistance, one of the most serious threats to global health and modern medicine. Bactiguard operates through license partnerships with leading global MedTech companies that apply the technology to their medical devices and sell them under their own brand or co- branded with Bactiguard. The company also has a portfolio of wound management products. Bactiguard is headquartered in Stockholm and listed on Nasdaq Stockholm. Read more about Bactiguard bactiguard.com Follow Bactiguard on LinkedIn Financial calendar 4 February 2027 Year-end report 1 January – 31 December 2026 31 March 2027 Annual Report 2026 22 April 2027 Interim report first quarter 1 January – 31 March 2027 13 July 2027 Interim report second quarter 1 April – 30 June 2027 21 October 2027 Interim report third quarter 1 July – 30 September 2027 Contacts For additional information, please contact: Patrick Bach, CFO: +46 8 440 58 80